36. Mihatsch MJ, Nicleleit V, Gudat F (1999) Morphologic criteria of chronic renal allograft rejection. *Transplant Proc* 31:1295–1297
37. Haas M, Sis B, Racusen LC et al (2014) Banff 2013 Meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. *Am J Transplant* 14:272–283
38. Mannon RB, Matas AJ, Grande J et al (2010) Inflammation in areas of tubular atrophy in kidney allograft biopsies: a potent predictor of allograft failure. *Am J Transplant* 10:2066–2073
39. Colvin RB, Smith RN (2005) Antibody-mediated organ-allograft rejection. *Nat Rev Immunol* 5:807–817
40. Einecke G, Sis B, Reeve J et al (2009) Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. *Am J Transplant* 9:2520–2531
41. Gaston RS, Cecka JM, Kasiske BL et al (2010) Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure. *Transplantation* 90:68–74
42. Regele H, Exner M, Watschinger B et al (2001) Endothelial C4d deposition is associated with inferior kidney allograft outcome independently of cellular rejection. *Nephrol Dial Transplant* 16:2058–2066
43. Kisseleva T, Brenner DA (2008) Mechanisms of fibrogenesis. *Exp Biol Med* (Maywood) 233:109–122
44. Kluth DC, Erwig LP, Rees AJ (2004) Multiple facets of macrophages in renal injury. *Kidney Int* 66:542–557
45. Halloran PF, Reeve JP, Pereira AB et al (2014) Antibody-mediated rejection, T cell-mediated rejection, and the injury-repair response: new insights from the Genome Canada studies of kidney transplant biopsies. *Kidney Int* 85:258–264
46. Halloran PF (2010) T cell-mediated rejection of kidney transplants: a personal viewpoint. *Am J Transplant* 10:1126–1134
47. Park WD, Griffin MD, Cornell LD et al (2010) Fibrosis with inflammation at one year predicts transplant functional decline. *J Am Soc Nephrol* 21:1987–1997
48. Shishido S, Asanuma H, Nakai H et al (2003) The impact of repeated subclinical acute rejection on the progression of chronic allograft nephropathy. *J Am Soc Nephrol* 14:1046–1052
49. Sellares J, Freitas DG de, Mengel M et al (2012) Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. *Am J Transplant* 12:388–399
50. Lefaucheur C, Viglietti D, Bentelejewski C et al (2015) IgG donor-specific anti-human hla antibody subclasses and kidney allograft antibody-mediated injury. *J Am Soc Nephrol* (im Druck)
51. Dragun D, Catar R, Philippe A (2013) Non-HLA antibodies in solid organ transplantation: recent concepts and clinical relevance. *Curr Opin Organ Transplant* 18:430–435
52. Ivanyi B (2003) Transplant capillaropathy and transplant glomerulopathy: ultrastructural markers of chronic renal allograft rejection. *Nephrol Dial Transplant* 18:655–660
53. Mengel M, Sis B, Haas M et al (2012) Banff 2011 Meeting report: new concepts in antibody-mediated rejection. *Am J Transplant* 12:563–570
54. Sis B, Jhangri GS, Bunnag S et al (2009) Endothelial gene expression in kidney transplants with alloantibody indicates antibody-mediated damage despite lack of C4d staining. *Am J Transplant* 9:2312–2323
55. Lucas JG, Co JP, Nwaogwugwu UT et al (2011) Antibody-mediated rejection in kidney transplantation: an update. *Expert Opin Pharmacother* 12:579–592
56. Fehr T, Gaspert A (2012) Antibody-mediated kidney allograft rejection: therapeutic options and their experimental rationale. *Transpl Int* 25:623–632
57. Pefaur J, Diaz P, Panace R et al (2008) Early and late humoral rejection: a clinicopathologic entity in two times. *Transplant Proc* 40:3229–3236
58. Sun Q, Liu ZH, Ji S et al (2006) Late and early C4d-positive acute rejection: different clinico-histopathological subentities in renal transplantation. *Kidney Int* 70:377–383
59. Walsh RC, Brailey P, Girmata A et al (2011) Early and late acute antibody-mediated rejection differ immunologically and in response to proteasome inhibition. *Transplantation* 91:1218–1226
60. Everly MJ, Everly JJ, Susskind B et al (2008) Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. *Transplantation* 86:1754–1761
61. Waiser J, Budde K, Schutz M et al (2012) Comparison between bortezomib and rituximab in the treatment of antibody-mediated renal allograft rejection. *Nephrol Dial Transplant* 27:1246–1251
62. Eskandary F, Bond G, Schwaiger E et al (2014) Bortezomib in late antibody-mediated kidney transplant rejection (BORTEJECT Study): study protocol for a randomized controlled trial. *Trials* 15:107
63. ClinicalTrials.gov. <http://clinicaltrials.gov/show/NCT01630538>. Zugriffen: 6. Dezember 2015
64. Ishida H, Omoto K, Shimizu T et al (2008) Usefulness of splenectomy for chronic active antibody-mediated rejection after renal transplantation. *Transpl Int* 21:602–604
65. Stegall MD, Diwan T, Raghavaiah S et al (2011) Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. *Am J Transplant* 11:2405–2413
66. Cornell LD, Schinstock CA, Gandhi MJ et al (2015) Positive crossmatch kidney transplant recipients treated with eculizumab: outcomes beyond 1 year. *Am J Transplant* 15:1293–1302

Internist 2016 · 57:37
 DOI 10.1007/s00108-015-3855-0
 Online publiziert: 19. Dezember 2015
 © Springer-Verlag Berlin Heidelberg 2015

B.C. Frye · J.C. Schupp · T.C. Köhler · J. Müller-Quernheim

Klinik für Pneumologie, Department Innere Medizin, Universitätsklinikum Freiburg, Freiburg

Erratum zu: Diagnostik und Therapie der Sarkoidose. Was ist gesichert?

Im Namen des Autors T.C. Köhler wurde leider eine falsche Initialie abgedruckt. Die Redaktion bittet, den Fehler zu entschuldigen und die korrekte Version zu beachten.

Korrespondenzadresse

Prof. Dr. J. Müller-Quernheim
 Klinik für Pneumologie, Department Innere Medizin, Universitätsklinikum Freiburg
 Killianstr. 5, 79106 Freiburg
direktion-pneumologie@uniklinik-freiburg.de